SNP

Global SNP Genotyping Market: China Emerges as Key Growth Driver with 18.1% CAGR

Retrieved on: 
Thursday, August 24, 2023
Livestock, Compound annual growth rate, Microarray, SNP, SNP genotyping, Single-nucleotide polymorphism, Growth, Agricultural biotechnology, Breeding

DUBLIN, Aug. 23, 2023 /PRNewswire/ -- The "SNP Genotyping and Analysis: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 23, 2023 /PRNewswire/ -- The "SNP Genotyping and Analysis: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The market is expected to experience a robust Compound Annual Growth Rate (CAGR) of 18.8% over the analysis period from 2022 to 2030.
  • Among the key segments, SNP Genotyping by Microarrays and GeneChips is anticipated to exhibit strong growth with a projected CAGR of 22.3%, reaching $20.9 billion by the end of the analysis period.
  • This data aims to provide a comprehensive understanding of the trends, growth opportunities, and market dynamics in the global SNP Genotyping and Analysis industry across different geographic regions, methods, and applications.

Pharmacogenomics Industry Landscape 2023-2027: Personalized Medicine Propels Growth, Global Market Set for Robust Expansion

Retrieved on: 
Wednesday, August 23, 2023
Biotechnology, Prevalence, ADR, Health, Polypharmacy, Personalized medicine, Cancer, Quality of life, Medicine, Research, Mass spectrometry, USD, ADR Institute of Alberta, IPMP, Crohn's disease, Hospital, Patient, Investment, Risk, SNP, Disease, Pain management, Drug discovery, Hospital Clinic Manuel Quintela, Growth, Conditional sentence, Mortality, Psychiatry, Neurology, PCR, National Institute for Health and Care Excellence, Pharmaceutical industry

The global pharmacogenomics market is poised for robust growth during the forecast period, driven by the increasing adoption of personalized medicine in healthcare.

Key Points: 
  • The global pharmacogenomics market is poised for robust growth during the forecast period, driven by the increasing adoption of personalized medicine in healthcare.
  • Additionally, the influx of research and development activities and the entry of companies into the personalized medicine arena are set to create promising opportunities for market growth.
  • A notable example is Infosys Limited's launch of personalized medicine solutions for the pharmaceutical industry in 2020, aiming to transform processes and drive better business outcomes.
  • The foundation of pharmacogenomics lies in precision medicine, and the rising adoption of personalized medicine further bolsters the market's growth prospects.

EQS-News: SNP: Public Takeover Offer Completed – Transition to Dualistic Management System Planned

Retrieved on: 
Tuesday, August 22, 2023
Supervisory board, Extraordinary general meeting, SAP, Accounting, RTÉ Executive Board, SNP, Growth, Environment, Security (finance), Management

Heidelberg, August 16, 2023 – After completion of the public takeover, Heidelberg businessman Wolfgang Marguere now directly and indirectly holds 63.8% of SNP Schneider-Neureither & Partner SE’s shares.

Key Points: 
  • Heidelberg, August 16, 2023 – After completion of the public takeover, Heidelberg businessman Wolfgang Marguere now directly and indirectly holds 63.8% of SNP Schneider-Neureither & Partner SE’s shares.
  • The takeover offer reduced the free float* of SNP shares to approx.
  • As the new majority shareholder, Wolfgang Marguerre intends to promote the long-term success of SNP in a sustainable manner.
  • Furthermore, SNP SE’s management system will be changed from a monistic system with a Board of Directors to the dualistic management system standard for German listed companies with an Executive Board and a Supervisory Board.

OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Communication, De novo, Classification, Nucleotide, UTI, European Patent Office, Infection, Curetis, Thermo Fisher Scientific, AMR, IP, Sale, Nadine Opgen-Rhein, Single-nucleotide polymorphism, Urinary tract infection, Patent, SNP, Medicine, European Patent Convention, Plasmid, IVD, FDA, Ares, Pneumonia, Video game, Pharmaceutical industry, Q2

ET

Key Points: 
  • ET
    ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 financial and operating results.
  • Second Quarter 2023 and First Half 2023 Financial Results of OpGen, Inc.
    Total revenue for the second quarter of 2023 was approximately $0.7 million compared to the company’s revenue of approximately $1.0 million in the second quarter of 2022, which was primarily driven by the one-time sale of a pool of Unyvero instrument systems to Menarini in Q2-2022.
  • Total operating expenses decreased in the second quarter of 2023 to approximately $5.9 million compared to approximately $6.2 million for the second quarter of 2022.
  • ET, to review the second quarter 2023 financial results and business activities, but will not be taking any questions.

Amida Care Celebrates 20 Years of Improving Health Outcomes for New Yorkers Impacted by HIV

Retrieved on: 
Tuesday, August 8, 2023
Post-exposure prophylaxis, Acacia, HIV/AIDS, PEP, Medicaid, Partnership, HIV, Homelessness, Village Care of New York, Feedback, Policy, Pre-exposure prophylaxis, Attention, History, Black, Vidacare Corporation, Hepatitis C, Thought, Social, Organization, Black AIDS Institute, Amida Care, Pharmacist, New Yorker, Trauma, SNP, Nursing, Health, Community Healthcare Network, Housing Works, Diagnosis, Racism, Death, Substance abuse, Pharmaceutical industry, Vaccine, Health insurance

NEW YORK, Aug. 8, 2023 /PRNewswire/ -- This month, Amida Care, a not-for-profit health plan specializing in providing comprehensive health coverage and coordinated care to people affected by HIV, celebrates 20 years of serving New Yorkers. The visionary plan was formed in August 2003 by community-based HIV service providers and has grown into New York's largest Medicaid managed care Special Needs Health Plan (SNP). Since its founding, Amida Care has taken a unique and innovative approach, thinking outside the box to put the needs of its members above all else, working in partnership with the providers who serve them, and playing an instrumental role in efforts to end the HIV/AIDS epidemic.

Key Points: 
  • –Amida Care currently serves over 9,000 New Yorkers affected by HIV, including 2,800 members who identify as transgender, gender nonconforming, and non-binary–
    NEW YORK, Aug. 8, 2023 /PRNewswire/ -- This month, Amida Care, a not-for-profit health plan specializing in providing comprehensive health coverage and coordinated care to people affected by HIV, celebrates 20 years of serving New Yorkers.
  • Amida Care has had tremendous success improving health outcomes for its members.
  • Amida Care Inc. is a not-for-profit health plan that specializes in providing comprehensive health coverage and coordinated care to New Yorkers with complex conditions, including HIV and behavioral health disorders, and people who are of transgender experience or who are homeless (regardless of HIV status).
  • Amida Care has a wide network of health care providers throughout New York City and is the largest Medicaid Special Needs Health Plan (SNP) in New York State.

OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering

Retrieved on: 
Monday, August 7, 2023
Informatics, SOCS2, Infection, Genomics, AMR, Nadine Opgen-Rhein, Houston, Laboratory, SNP, Medicine, Plasmid, WGS, Health, Ares, HIPAA, Vaccine, Antibiotics, Q3

Working with its customers globally, the Ares team has developed the new AREScloud features to provide relevant reporting for hospital epidemiologists and infection preventionists.

Key Points: 
  • Working with its customers globally, the Ares team has developed the new AREScloud features to provide relevant reporting for hospital epidemiologists and infection preventionists.
  • The new AREScloud features are now deployed as part of the standard analysis package, and in use with our customers globally.
  • The new features further broaden the capabilities of AREScloud for microbial genomics that include antimicrobial resistance profiling, and genomic antibiotic sensitivity testing.
  • To support this goal, we continue to enhance our AREScloud features, while making pathogen sequencing both affordable and broadly available.”

EQS-News: SNP continues on its growth path with order entry up by more than 30% in the second quarter – EBIT also increases significantly

Retrieved on: 
Friday, August 4, 2023
Partnership, Data stream, Annual, Snowflake Inc., SAP, EBIT, Sale, SAP S/4HANA, Data, SNP, Security (finance), Rare-earth element, Video game, Cryptocurrency, Central Europe

Despite negative currency effects and one-off extraordinary charges, EBIT improved in the second quarter to € 1.0 million (Q2 2022: € 0.7 million).

Key Points: 
  • Despite negative currency effects and one-off extraordinary charges, EBIT improved in the second quarter to € 1.0 million (Q2 2022: € 0.7 million).
  • Jens Amail, CEO of SNP, commented: “We posted strong growth rates in order entry, revenue and earnings also in the second quarter of the current fiscal year.
  • Furthermore, the high order entry volume generated via our partners and the sharp rise in software revenue are clear signals that we are on a good path.
  • At € 55.1 million, SAP S/4HANA projects meanwhile account for around 50% of the SNP Group's total order entry.

EQS-News: SNP SE reorganizes its Board of Directors

Retrieved on: 
Wednesday, August 2, 2023
Heidelberg, Audit committee, Vice, Supervisory board, Software, SNP, Management

Dr. Karl Benedikt Biesinger becomes Chairman of the Board of Directors; Prof. Dr. Thorsten Grenz takes over as Vice Chairman.

Key Points: 
  • Dr. Karl Benedikt Biesinger becomes Chairman of the Board of Directors; Prof. Dr. Thorsten Grenz takes over as Vice Chairman.
  • Heidelberg, August 2, 2023 – Software and consulting company SNP Schneider-Neureither & Partner SE has reorganized its Board of Directors.
  • At yesterday’s meeting of SNP’s Board of Directors, the previous Deputy Chairman, Dr. Karl Benedikt Biesinger, was elected Chairman, and Prof. Dr. Thorsten Grenz was elected as his deputy.
  • “I look forward to working with the new Board of Directors chaired by Dr. Karl Benedikt Biesinger, and I support the transition to the dualistic system,” says Jens Amail, CEO of SNP.

Foresee Pharmaceuticals Selected for Late-Breaking Oral Presentation on its Aderamastat Phase 2 Study Results at the European Respiratory Society (ERS) International Congress 2023

Retrieved on: 
Tuesday, July 25, 2023
Lung, Human, Asthma, Foresight, SNP, Pharmaceutical industry

"We are very excited to have the opportunity to present promising data related to the previously announced aderamastat topline Phase 2 proof-of-concept study.

Key Points: 
  • "We are very excited to have the opportunity to present promising data related to the previously announced aderamastat topline Phase 2 proof-of-concept study.
  • The data strongly support the role of MMP-12 in key inflammatory pathways that contribute to asthma and other lung diseases," said Dr. Yisheng Lee, Chief Medical Officer at Foresee.
  • We could not be more confident with the role and importance of MMP-12 in immune-fibrotic diseases, particularly in the lung," added Dr. Lee.
  • The presentation will be available on the Foresee website after the conference.

Foresee Pharmaceuticals Selected for Late-Breaking Oral Presentation on its Aderamastat Phase 2 Study Results at the European Respiratory Society (ERS) International Congress 2023

Retrieved on: 
Tuesday, July 25, 2023
Lung, Human, Asthma, Foresight, SNP, Pharmaceutical industry

"We are very excited to have the opportunity to present promising data related to the previously announced aderamastat topline Phase 2 proof-of-concept study.

Key Points: 
  • "We are very excited to have the opportunity to present promising data related to the previously announced aderamastat topline Phase 2 proof-of-concept study.
  • The data strongly support the role of MMP-12 in key inflammatory pathways that contribute to asthma and other lung diseases," said Dr. Yisheng Lee, Chief Medical Officer at Foresee.
  • We could not be more confident with the role and importance of MMP-12 in immune-fibrotic diseases, particularly in the lung," added Dr. Lee.
  • The presentation will be available on the Foresee website after the conference.